CNSP
CNS Pharmaceuticals Inc
NASDAQ: CNSP · HEALTHCARE · BIOTECHNOLOGY
$2.27
+0.44% today
Updated 2026-04-30
Market cap
$1.91M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-35.75
Dividend yield
—
52W range
$2 – $17
Volume
0.0M
CNS Pharmaceuticals Inc (CNSP) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | $1955.00 | $11096.00 | $13070.00 | $11756.00 | $4134.00 | $3306.00 | — |
| Gross profit | — | — | $-1955.00 | $-11096.00 | $-13070.00 | $-11756.00 | $-4134.00 | $-3306.00 | — |
| Gross margin | — | — | — | — | — | — | — | — | — |
| R&D | $32638.00 | $21267.00 | $1.85M | $5.06M | $9.81M | $9.30M | $14.10M | $9.29M | $9.77M |
| SG&A | $437921.00 | $860520.00 | $1.98M | $4.39M | $4.68M | $5.97M | $4.77M | $5.61M | $6.21M |
| Operating income | $-516252.00 | $-881787.00 | $-3.83M | $-9.45M | $-14.49M | $-14.93M | $-18.87M | $-14.90M | $-15.99M |
| Operating margin | — | — | — | — | — | — | — | — | — |
| EBITDA | — | $-6.46M | $-3.83M | $-9.44M | $-14.47M | $-15.26M | $-18.86M | $-14.84M | $-15.83M |
| EBITDA margin | — | — | — | — | — | — | — | — | — |
| EBIT | $-516252.00 | $-7.35M | $-3.83M | $-9.45M | $-14.49M | $-15.27M | $-18.87M | $-14.84M | $-15.84M |
| Interest expense | $4257.00 | $46697.00 | $44234.00 | $3264.00 | $9285.00 | $7027.00 | $13805.00 | $16119.00 | $15230.00 |
| Income tax | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-526469.00 | $-7.39M | $-3.92M | $-9.46M | $-14.50M | $-15.27M | $-18.85M | $-14.86M | $-15.85M |
| Net income growth (YoY) | — | -1304.1% | +47.0% | -141.3% | -53.3% | -5.4% | -23.4% | +21.2% | -6.7% |
| Profit margin | — | — | — | — | — | — | — | — | — |